Protocols
13 protocol(s) meet the specified criteria
Disease Site: Ovary
Protocol No.TitleStatus
B8011001A Phase 1, Open-Label, Dose Escalation and Expansion Study of PF-06801591 in Patients with Locally Advanced or Metastatic Melanoma, Squamous Cell Head and Neck Cancer, Ovarian Cancer, Sarcoma, or Relapsed or Refractory Classic Hodgkin Lymphoma or Other Solid TumorsOpen
D6410C00001A Phase I, First-Time-in Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally in Subjects with Solid Tumor CancerOpen
GOG-0225Can Diet and Physical Activity Modulate Ovarian, fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?Open
GOG-0264A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary Open
GOG-0281 A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal CancerOpen
GOG212A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND # 70177), Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Who Acheive a Complete Clinical Response to Primary Platinum/Taxane ChemotherapyOpen (affiliates only)
GOG3005-M13-694A Phase 3 Placebo-controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serious Epithelial Ovarian, Fallopian tube, or Primary Peritoneal Cancer (M13-694 Protocol)Open
LCCC1538Geriatric Assessment Reporting in Real Time (GARRT) in non-electively hospitalized older cancer patients: feasibility, impact, and clinician acceptance.Open
MCC-16962A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid TumorsOpen
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
MM-398-01-01-02A Phase 1 Study in Patients Treated with MM-398 (Nanoliposomal Irinotecan, nal-IRI,) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to TreatmentOpen
MORAB-003-011A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian CancerOpen
NRG-GY005A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)Open